2018 Global AI-based Pathology Solutions in Immuno-oncology Technology Innovation Award

Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc. (Flagship) with the 2018 Global Technology Innovation Award.

Each year, Frost & Sullivan presents this award to the company that develops a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.

“Flagship was one of the early adopters of digital pathology, leveraging AI-based image analysis methods to generate reproducible, quantifiable, precise data to aid decision-making through the entire drug development process,” said Unmesh Lal, Program Manager at Frost & Sullivan. “Its cTA® platform generates vast amounts of cell-specific biological measurements, such as spatial tissue organization, as well as cellular interactions and architectures, to deliver data-rich tissue content identifying immune cell infiltration within the tumor microenvironment. Flagship’s team then interprets these profiles, characterizes patient-specific immunomodulation, and predicts patient response to cancer immunotherapies.”

Learn more: Frost & Sullivan News Release, September 18, 2018

Share This Post: